請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10011
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 方俊民(Jim-Min Fang) | |
dc.contributor.author | Joshua Lai | en |
dc.contributor.author | 賴怡禎 | zh_TW |
dc.date.accessioned | 2021-05-20T20:55:39Z | - |
dc.date.available | 2011-08-22 | |
dc.date.available | 2021-05-20T20:55:39Z | - |
dc.date.copyright | 2011-08-22 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-22 | |
dc.identifier.citation | [1] Webster, R. G.; Bean, W. J.; Gorman, O. T.; Chambers, T. M.; Kawaoka, Y.
Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992, 56, 152–179. [2] Webster, R. G.; Yakhno, M.; Hinshaw, V. S.; Bean, W. J.; Murti, K. G. Intestinal influenza: replication and characterization of influenza viruses in ducks. Virology 1978, 84, 268–278. [3] Johnson, N. P. A. S.; Mueller, J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull. Hist. Med. 2002, 76, 105–115. [4] Reid, A. H.; Taubenberger, J. K. The origin of the 1918 pandemic influenza virus: a continuing enigma. J. Gen. Virol. 2003, 84, 2285–2292. [5] Simonsen, L.; Clarke, M. J.; Schonberger, L. B.; Arden, N. H.; Cox, N. J.; Fukuda, K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis. 1998, 178, 53–60. [6] Gamblin, S. J.; Haire, L. F.; Russell, R. J.; Stevens, D. J.; Xiao, B.; Ha, Y.; Vasisht, N.; Steinhauer, D. A.; Daniels, R. S.; Elliot, A.; Wiley, D. C.; Skehel, J. J. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004, 303, 1838–1842. [7] Stevens, J.; Corper, A. L.; Basler, C. F.; Taubenberger, J. K.; Palese, P.;Wilson, I. A. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004, 303, 1866–1870. [8] Helenius, A. Unpacking the incoming influenza virus. Cell 1992, 69, 577–578. [9] Ciampor, F.; Bayley, P. M.; Nermut, M. V.; Hirst, E. M.; Sugrue, R. J.; Hay, A. J. Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment. Virology 1992, 188, 14–24. [10] Chizhmakov, I. V.; Geraghty, F. M.; Ogden, D. C.; Hayhurst, A.; Antoniou, M.; Hay, A. J. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J. Physiol. 1996, 494 ( Pt 2), 329–336. [11] Wang, C.; Takeuchi, K.; Pinto, L. H.; Lamb, R. A. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 1993, 67, 5585–5594. [12] Pinto, L. H.; Holsinger, L. J.; Lamb, R. A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69, 517–528. [13] Hay, A. J.; Wolstenholme, A. J.; Skehel, J. J.; Smith, M. H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4, 3021–3024. [14] Holsinger, L. J.; Lamb, R. A. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991, 183, 32– 43. [15] Sugrue, R. J.; Hay, A. J. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991, 180, 617–624. [16] Tang, Y.; Zaitseva, F.; Lamb, R. A.; Pinto, L. H. The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue. J. Biol. Chem. 2002, 277, 39880–39886. [17] Pinto, L. H.; Dieckmann, G. R.; Gandhi, C. S.; Papworth, C. G.; Braman, J.; Shaughnessy, M. A.; Lear, J. D.; Lamb, R. A.; DeGrado, W. F. A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc. Natl. Acad. Sci. USA 1997, 94, 11301–11306. [18] Das, K.; Aramini, J. M.; Ma, L.-C.; Krug, R. M.; Arnold, E. Structures of influenza A proteins and insights into antiviral drug targets. Nat. Struct. Mol. Biol. 2010, 17, 530–538. [19] Cady, S. D.; Schmidt-Rohr, K.; Wang, J.; Soto, C. S.; Degrado, W. F.; Hong, M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010, 463, 689–692. [20] Rogers, G. N.; D’Souza, B. L. Receptor binding properties of human and animal H1 influenza virus isolates. Virology 1989, 173, 317–322. [21] Steinhauer, D. A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999, 258, 1–20. [22] Colman, P. M.; Hoyne, P. A.; Lawrence, M. C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 1993, 67, 2972–2980. [23] Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119, 681–690. [24] von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418–423. [25] Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin, Y. P.; Blackburn, G. M.; Hay, A. J.; Gamblin, S. J.; Skehel, J. J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443, 45– 49. [26] Wu, W. W.; Pante, N. The directionality of the nuclear transport of the influenza A genome is driven by selective exposure of nuclear localization sequences on nucleoprotein. Virol. J. 2009, 6, 68. [27] Ulmanen, I.; Broni, B. A.; Krug, R. M. Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc. Natl. Acad. Sci. USA 1981, 78, 7355–7359. [28] Plotch, S. J.; Bouloy, M.; Ulmanen, I.; Krug, R. M. A unique cap(m7GpppXm)- dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 1981, 23, 847–858. [29] Shimizu, K.; Iguchi, A.; Gomyou, R.; Ono, Y. Influenza virus inhibits cleavage of the HSP70 pre-mRNAs at the polyadenylation site. Virology 1999, 254, 213–219. [30] Nemero , M. E.; Barabino, S. M.; Li, Y.; Keller, W.; Krug, R. M. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 30 end formation of cellular pre-mRNAs. Mol. Cell 1998, 1, 991–1000. [31] Neumann, G.; Hughes, M. T.; Kawaoka, Y. Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO J. 2000, 19, 6751–6758. [32] Maugh, T. H. Amantadine: an alternative for prevention of influenza. Science 1976, 192, 130–131. [33] Rosenberg, M. R.; Casarotto, M. G. Coexistence of two adamantane binding sites in the influenza A M2 ion channel. Proc. Natl. Acad. Sci. USA 2010, 107, 13866– 13871. [34] Palese, P.; Compans, R. W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J. Gen. Virol. 1976, 33, 159–163. [35] Palese, P.; Schulman, J. L.; Bodo, G.; Meindl, P. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-Ntrifluoroacetylneuraminic acid (FANA). Virology 1974, 59, 490–498. [36] Meindl, P.; Bodo, G.; Palese, P.; Schulman, J.; Tuppy, H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1974, 58, 457–463. [37] Colman, P. M.; Varghese, J. N.; Laver,W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983, 303, 41–44. [38] Varghese, J. N.; Epa, V. C.; Colman, P. M. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci. 1995, 4, 1081–1087. [39] Varghese, J. N.; McKimm-Breschkin, J. L.; Caldwell, J. B.; Kortt, A. A.; Colman, P. M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992, 14, 327–332. [40] Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T. H.; Hutchison, T. L.; Elliott, A. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Laver, G. W.; Montgomery, J. A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43, 3482–3486. [41] Bossart-Whitaker, P.; Carson, M.; Babu, Y. S.; Smith, C. D.; Laver,W. G.; Air, G. M. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J. Biol. Chem. 1993, 232, 1069–1083. [42] Macdonald, S. J. F.; Cameron, R.; Demaine, D. A.; Fenton, R. J.; Foster, G.; Gower, D.; Hamblin, J. N.; Hamilton, S.; Hart, G. J.; Hill, A. P.; Inglis, G. G. A.; Jin, B.; Jones, H. T.; McConnell, D. B.; McKimm-Breschkin, J.; Mills, G.; Nguyen, V.; Owens, I. J.; Parry, N.; Shanahan, S. E.; Smith, D.; Watson, K. G.; Wu, W.-Y.; Tucker, S. P. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem. 2005, 48, 2964–2971. [43] Macdonald, S. J. F.; Watson, K. G.; Cameron, R.; Chalmers, D. K.; Demaine, D. A.; Fenton, R. J.; Gower, D.; Hamblin, J. N.; Hamilton, S.; Hart, G. J.; Inglis, G. G. A.; Jin, B.; Jones, H. T.; McConnell, D. B.; Mason, A. M.; Nguyen, V.; Owens, I. J.; Parry, N.; Reece, P. A.; Shanahan, S. E.; Smith, D.; Wu, W.-Y.; Tucker, S. P. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are e ective at a once-weekly dosing regimen. Antimicrob. Agents Chemother. 2004, 48, 4542–4549. [44] Yamashita, M.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Nasu, H.; Kubo, S. CS8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53, 186–192. [45] Lew, W.; Chen, X.; Kim, C. Discovery and development of GS 4104 (oseltamivir): An orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 2000, 7, 663– 672. [46] Knop, D. R.; Draths, K. M.; Chandran, S. S.; Barker, J. L.; von Daeniken, R.; Weber,W.; Frost, J.W. Hydroaromatic equilibration during biosynthesis of shikimic acid. J. Am. Chem. Soc. 2001, 123, 10173–10182. [47] Nie, L.-D.; Shi, X.-X.; Ko, K. H.; Lu, W.-D. A short and practical synthesis of oseltamivir phosphate (Tamiflu) from (–)-shikimic acid. J. Org. Chem. 2009, 74, 3970–3973. [48] Karpf, M.; Trussardi, R. E cient access to oseltamivir phosphate (Tamiflu) via the O-trimesylate of shikimic acid ethyl ester. Angew. Chem. Int. Ed. 2009, 48, 5760– 5762. [49] Ma, J.; Zhao, Y.; Ng, S.; Zhang, J.; Zeng, J.; Than, A.; Chen, P.; Liu, X.-W. Sugar- Based Synthesis of Tamiflu and Its Inhibitory E ects on Cell Secretion. Chem. Eur. J. 2010, 16, 4533–4540. [50] Osato, H.; Jones, I. L.; Chen, A.; Chai, C. L. L. E cient formal synthesis of oseltamivir phosphate (Tamiflu) with inexpensive d-ribose as the starting material. Org. Lett. 2010, 12, 60–63. [51] Shie, J.-J.; Fang, J.-M.; Wang, S.-Y.; Tsai, K.-C.; Cheng, Y.-S. E.; Yang, A.-S.; Hsiao, S.-C.; Su, C.-Y.; Wong, C.-H. Synthesis of Tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J. Am. Chem. Soc. 2007, 129, 11892–11893. [52] Weng, J.; Li, Y.-B.; Wang, R.-B.; Li, F.-Q.; Liu, C.; Chan, A. S. C.; Lu, G. A practical and azide-free synthetic approach to oseltamivir from diethyl d-tartrate. J. Org. Chem. 2010, 75, 3125–3128. [53] Oshitari, T.; Mandai, T. Azide-free synthesis of oseltamivir from l-methionine. Synlett 2009, 787–789. [54] Mandai, T.; Oshitari, T. E cient asymmetric synthesis of oseltamivir from d- Mannitol. Synlett 2009, 783–786. [55] Cong, X.; Yao, Z.-J. Ring-closing metathesis-based synthesis of (3R,4R,5S)- 4-acetylamino-5-amino-3-hydroxycyclohex-1-ene-carboxylic acid ethyl ester: A functionalized cycloalkene skeleton of GS4104. J. Org. Chem. 2006, 71, 5365–5368. [56] Sun, H.; Lin, Y.-J.; Wu, Y.-L.; Wu, Y. A facile access to antiflu agent Tamiflu/oseltamivir. Synlett 2009, 2473–2476. [57] Yamatsugu, K.; Kanai, M.; Shibasaki, M. An alternative synthesis of Tamiflu: a synthetic challenge and the identification of a ruthenium-catalyzed dihydroxylation route. Tetrahedron 2009, 65, 6017–6024. [58] Yamatsugu, K.; Yin, L.; Kamijo, S.; Kimura, Y.; Kanai, M.; Shibasaki, M. A synthesis of Tamiflu by using a barium-catalyzed asymmetric Diels–Alder-type reaction. Angew. Chem. Int. Ed. 2009, 48, 1070–1076. [59] Yamatsugu, K.; Kamijo, S.; Suto, Y.; Kanai, M.; Shibasaki, M. A concise synthesis of Tamiflu: third generation route via the Diels–Alder reaction and the Curtius rearrangement. Tetrahedron Lett. 2007, 48, 1403–1406. [60] Yeung, Y.-Y.; Hong, S.; Corey, E. J. A short enantioselective pathway for the synthesis of the anti-influenza neuramidase inhibitor oseltamivir from 1,3-butadiene and acrylic acid. J. Am. Chem. Soc. 2006, 128, 6310–6311. [61] Ishikawa, H.; Suzuki, T.; Hayashi, Y. High-yielding synthesis of the anti-influenza neuramidase inhibitor (–)-oseltamivir by three “one-pot” operations. Angew. Chem. Int. Ed. 2009, 48, 1304–1307. [62] Trost, B. M.; Zhang, T. A concise synthesis of (–)-oseltamivir. Angew. Chem. Int. Ed. 2008, 47, 3759–3761. [63] Rohlo , J.; Kent, K.; Postich, M.; Becker, M.; Chapman, H.; Kelly, D.; Lew, W.; Louie, M.; McGee, L.; Prisbe, E.; Schultze, L.; Yu, R.; Zhang, L. Practical total synthesis of the anti-influenza drug GS-4104. J. Org. Chem. 1998, 63, 4545–4550. [64] Federspiel, M.; Fischer, R.; Hennig, M.; Mair, H.; Oberhauser, T.; Rimmler, G.; Albiez, T.; Bruhin, J.; Estermann, H.; Gandert, C.; Gockel, V.; Gotzo, S.; Ho mann, U.; Huber, G.; Janatsch, G.; Lauper, S.; Rockel-Stabler, O.; Trussardi, R.; Zwahlen, A. Industrial synthesis of the key precursor in the synthesis of the anti-influenza drug oseltamivir phosphate (Ro 64-0796/002, GS-4104-02): Ethyl (3R,4S,5S)-4,5-epoxy-3-(1-ethyl-propoxy)-cyclohex-1-ene-1- carboxylate. Org. Process Res. Dev. 1999, 3, 266–274. [65] Chini, M.; Crotti, P.; Favero, L.; Macchia, F.; Pineschi, M. Lanthanide(III) trifluoromethanesulfonates as extraodinarily e ective new catalysts for the aminolysis of 1,2-epoxides. Tetrahedron Lett. 1994, 35, 433–436. [66] Karpf, M.; Trussardi, R. New, azide-free transformation of epoxides into 1,2- diamino compounds: Synthesis of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu). J. Org. Chem. 2001, 66, 2044–2051. [67] Shie, J.-J.; Fang, J.-M.; Wong, C.-H. A concise and flexible synthesis of the potent anti-influenza agents tamiflu and tamiphosphor. Angew. Chem. Int. Ed. 2008, 47, 5788–5791. [68] Endoma, M.; Bui, V.; Hansen, J.; Hudlicky, T. Medium-scale preparation of useful metabolites of aromatic compounds via whole-cell fermentation with recombinant organisms. Org. Process Res. Dev. 2002, 6, 525–532. [69] Zutter, U.; Iding, H.; Spurr, P.; Wirz, B. New, e cient synthesis of oseltamivir phosphate (Tamiflu) via enzymatic desymmetrization of a meso-1,3- cyclohexanedicarboxylic acid diester. J. Org. Chem. 2008, 73, 4895–4902. [70] Sullivan, B.; Carrera, I.; Drouin, M.; Hudlicky, T. Symmetry-based design for the chemoenzymatic synthesis of oseltamivir (Tamiflu) from ethyl benzoate. Angew. Chem. Int. Ed. 2009, 48, 4229–4231. [71] Wichienukul, P.; Akkarasamiyo, S.; Kongkathip, N.; Kongkathip, B. An e cient synthesis of oseltamivir phosphate (Tamiflu) via a metal-mediated domino reaction and ring-closing metathesis. Tetrahedron Lett. 2010, 51, 3208–3210. [72] Nakane, M.; Hutchinson, C. R.; Gollman, H. Convinient and general synthesis of 5- vinylhexofuranosides from 6-halo-6-deoxypyranosides. Tetrahedron Lett. 1980, 21, 1213–1216. [73] Abrecht, S.; Harrington, P.; Iding, H.; Karpf, M.; Trussardi, R.; Wirz, B.; Zutter, U. The synthetic development of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu): a challenge for synthesis process research. Chimia 2004, 58, 621–629. [74] Satoh, N.; Akiba, T.; Yokoshima, S.; Fukuyama, T. A practical synthesis of (–)- Oseltamivir. Angew. Chem. Int. Ed. 2007, 46, 5734–5736. [75] Fukuta, Y.; Mita, T.; Fukuda, N.; Kanai, M.; Shibasaki, M. De novo synthesis of Tamiflu via a catalytic asymmetric ring-opening of meso-aziridines with TMSN3. J. Am. Chem. Soc. 2006, 128, 6312–6313. [76] Bromfield, K. M.; Graden, H.; Hagberg, D. P.; Olsson, T.; Kann, N. An iron carbonyl approach to the influenza neuraminidase inhibitor oseltamivir. Chem. Commun. 2007, 3183–3185. [77] Zhu, S.; Yu, S.; Wang, Y.; Ma, D. Organocatalytic Michael addition of aldehydes to protected 2-amino-1-nitroethenes: the practical syntheses of oseltamivir (Tamiflu) and substituted 3-aminopyrrolidines. Angew Chem Int Ed Engl 2010, 49, 4656– 4660. [78] Shibasaki, M.; Kanai, M. Synthetic strategies for oseltamivir phosphate. Eur. J. Org. Chem. 2008, 1839–1850. [79] Dondoni, A.; Perrone, D. Synthesis of 1,1-dimethylethyl (S)-4-formyl-2,2-dimethyl- 3-oxazolidinecarboxylate by oxidation of the alcohol. Organic Syntheses 2000, 77, 64–77. [80] Coleman, R. S.; Carpenter, A. J. Diaselective addition of vinyl organometallic reagents to l-serinal. Tetrahedron Lett. 1992, 33, 1697–1700. [81] Srivastava, A. K.; Panda, G. Total synthesis of (–)-balanol, all stereoisomers, their Ntosyl analogues, and fully protected ophiocordin: an easy route to hexahydroazepine cores from garner aldehydes. Chem. Eur. J. 2008, 14, 4675–4688. [82] Eckenberg, P.; Groth, U.; Huhn, T.; Richter, N.; Schmeck, C. A useful application of benzyl trichloroacetimidate for the benzylation of alcohols. Tetrahedron 1993, 49, 1619–1624. [83] Takahata, H.; Banba, Y.; Sasatani, M.; Nemoto, H.; Kato, A.; Adachi, I. Asymmetric synthesis of 1-deoxynojirimycin and its congeners from a common chiral building block. Tetrahedron 2004, 60, 8199–8205. [84] Vougioukalakis, G. C.; Grubbs, R. H. Ruthenium-based heterocyclic carbenecoordinated olefin metathesis catalysts. Chem. Rev. 2010, 110, 1746–1787. [85] Mita, T.; Fukuda, N.; Roca, F. X.; Kanai, M.; Shibasaki, M. Second generation catalytic asymmetric synthesis of tamiflu: allylic substitution route. Org. Lett. 2007, 9, 259–262. [86] Lipshutz, B. H.; Chung, D. W.; Rich, B.; Corral, R. Simplification of the Mitsunobu reaction. Di-p-chlorobenzyl azodicarboxylate: a new azodicarboxylate. Org. Lett. 2006, 8, 5069–5072. [87] Kim, Y.-A.; Chung, H.-M.; Park, J.-S.; Choi, W.; Min, J.; Park, N.-H.; Kim, K.-H.; Jhon, G.-J.; Han, S.-Y. Synthesis of novel lysophosphatidylcholine analogues using serine as chiral template. J. Org. Chem. 2003, 68, 10162–10165. [88] Micale, N.; Kozikowski, A. P.; Ettari, R.; Grasso, S.; Zappala, M.; Jeong, J.-J.; Kumar, A.; Hanspal, M.; Chishti, A. H. Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents. J. Med. Chem. 2006, 49, 3064–3067. [89] Martin, N. I.; Woodward, J. J.; Winter, M. B.; Marletta, M. A. 4,4-Difluorinated analogues of l-arginine and NG-hydroxy-l-arginine as mechanistic probes for nitric oxide synthase. Bioorg. Med. Chem. Lett. 2009, 19, 1758–1762. [90] Yadav, J.; Reddy, B.; Basak, A.; Narsaiah, A. Recyclable 2nd generation ionic liquids as green solvents for the oxidation of alcohols with hypervalent iodine reagents. Tetrahedron 2004, 60, 2131–2135. [91] Takahata, H.; Banba, Y.; Ouchi, H.; Nemoto, H. Concise and highly stereocontrolled synthesis of 1-deoxygalactonojirimycin and its congeners using dioxanylpiperidene, a promising chiral building block. Org. Lett. 2003, 5, 2527–2529. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10011 | - |
dc.description.abstract | 近來,新型流感數度襲捲全球,除了導致嚴重的經濟衝擊,更造成大量無辜生命的喪失。由於流感能藉由兩種主要的突變路徑---抗原漂移 (antigen drift) 及抗原轉移 (antigen shift) 來達到產生高致病性的新型流感病毒,因此人類缺乏對於這種新型流感的免疫能力,這樣不對等的關係也造成了整個社會的恐慌。
在過去的一些研究中,Hoffmann La-Roche Ltd. 及 GlaxoSmithKline 分別開發出針對唾液酸水解酶 (Neuraminidase) 的抑制劑---克流感 (Tamiflu) 及瑞樂沙 (Relenza),這兩種藥物藉由設計成模擬唾液酸水解酶的受質被水解時的過渡態,使得病毒即便在感染宿主細胞後,也無法順利的將其子代釋出,進而造成病毒的凋亡。然而由於瑞樂沙的分子設計,使得它的口服可利用率相當的低,它通常以鼻吸劑的方式被使用,這樣的方式對於年長者及嬰幼兒來說都相當不方便,因此克流感成為目前唯一可口服的唾液酸水解酶抑制劑,在克流感的工業法合成上是以莽草酸 (Shikimic acid) 為起始物,但是莽草酸取得主要是透過八角這一類天然草藥的萃取,由於對有限的天然草藥的依賴,使得此工業合成方式無法滿足在流感大爆發期間的需求。 為了滿足這樣的需求,我們嘗試開發出一個以可大量取得的原料為起始物的合成方法,藉由逆合成分析克流感的有效藥物成份---奧司他偉 (oseltamivir) 的結構,我們推導出一個以 D-絲胺酸為起始物的合成方法,經由環閉合置換來建構環己烯及共軛酯基的中心骨架,並利用 D-絲胺酸上的掌性中心來建構在奧司他偉上另外兩個掌性中心。 在這個合成方法中我們成功整合了以下幾個關鍵性步驟: (a) 透過 Zn2+ 與 Garner's 醛螯合作用的乙烯基加成, (b) 利用銦來促使丙烯酸基進行 Reformatsky 反應,以及 (c) 環閉合置換反應。 | zh_TW |
dc.description.abstract | Recently, influenza has just swept worldwide and resulted in a severe crisis to human beings. Taking advantage of two mutation mechanisms---antigenic drift and antigenic shift, influenza virus can generate hybrid and highly pathogenic strains. The lack of immunities to these new influenza strains poses human into an unequal battle and even causes a worldwide panic.
Hoffmann La-Roche Ltd. and GlaxoSmithKline have developed two neuraminidase inhibitors---Tamiflu and Relenza against influenza virus. By mimicking the transition state of neuraminidase in the cleavage of sialic acid, these two drugs can block the release of the budding progenitors of influenza virus. However, the oral bioavailability of Relenza is relatively low due to the highly polar functionalities. The administration of Relenza is therefore limited in nasal inhalation which is not convenient to the elders and the infants. As a result, Tamiflu is the only orally available drug in the treatment of influenza virus. The industrial manufacture of oseltamivir, the active pharmaceutical ingredient of Tamiflu, starts from shikimic acid, which is mainly produced by extraction of star anise, a natural herb. When there were a pandemic, the limited resource of natural herb may not satisfy the demand for manufacturing oseltamivir in sufficient amount. For this reason, we design a new synthetic route to oseltamivir using commercially available D-serine as the starting material. The stereogenic center of D-serine not only controls the syn stereochemistry in the vinyl addition to Garner's aldehyde but also secures the three consecutive chiral centers in anti--anti relationship for oseltamivir. In this synthesis, we successfully integrate the following key reactions: (a) Zn2+ chelated vinyl addition to Garner's aldehyde, (b) indium promoted Reformatsky reaction of $alphaup$-(bromomethyl)acrylate in aqueous media, and (c) ring-closure metathesis. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:55:39Z (GMT). No. of bitstreams: 1 ntu-100-D92223027-1.pdf: 19857305 bytes, checksum: 50210461ff450f7ea078199446ee179c (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員會審定書i
Acknowledgments iii 誌謝v Abstract vii 中文摘要ix 1 Introduction 1 1.1 Influenza Virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1.1.1 Membrane Proteins . . . . . . . . . . . . . . . . . . . . . . . . . 3 1.1.2 Life Cycle of Influenza Virus . . . . . . . . . . . . . . . . . . . . 7 1.1.3 Antigenic Variation . . . . . . . . . . . . . . . . . . . . . . . . . 8 1.2 Therapies Against Influenza Virus . . . . . . . . . . . . . . . . . . . . . 9 1.2.1 M2 Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 1.2.2 NA Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 1.2.3 Supply Issue . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 1.3 Synthesis of Oseltamivir . . . . . . . . . . . . . . . . . . . . . . . . . . 12 1.3.1 Review of Diverse Synthetic Routes . . . . . . . . . . . . . . . . 13 1.3.2 Motivation of This Synthesis . . . . . . . . . . . . . . . . . . . . 41 2 Results and Discussion 43 2.1 Retrosynthetic Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 2.2 Synthesis of Oseltamivir from d-Serine . . . . . . . . . . . . . . . . . . . 45 2.2.1 Introduction of 3-Pentoxy Group . . . . . . . . . . . . . . . . . . 47 2.2.2 Reformatsky Type Allylation . . . . . . . . . . . . . . . . . . . . 50 2.2.3 Ring-closure Metathesis for Generation of Cyclohexene Core Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 2.2.4 Deprotection of Benzyl Group . . . . . . . . . . . . . . . . . . . 54 2.2.5 A Better Protecting Group . . . . . . . . . . . . . . . . . . . . . 58 2.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 3 Experimental Part 65 3.1 General Part . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 3.2 Procedures and Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Bibliography 95 NMR Spectra 107 | |
dc.language.iso | en | |
dc.title | 由D-絲胺酸進行克流感合成之探討 | zh_TW |
dc.title | Study of Oseltamivir Synthesis from D-Serine | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 汪根欉(Ken-Tsung Wong),羅禮強(Lee-Chiang Lo),陳焜銘(Kwunmin Chen),張哲健(Che-Chien Chang),陳榮傑(Rong-Jie Chein) | |
dc.subject.keyword | 克流感,流感病毒,唾液酸水解酶,抑制劑, | zh_TW |
dc.subject.keyword | Tamiflu,Oseltamivir,Influenza,Neuraminidase, | en |
dc.relation.page | 145 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2011-08-22 | |
dc.contributor.author-college | 理學院 | zh_TW |
dc.contributor.author-dept | 化學研究所 | zh_TW |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf | 19.39 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。